Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Difenoxin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.73 |
| ▸ | KCNA3 | P22001 | 9/20 | 0.76 |
| ▸ | CCR1 | P32246 | 6/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | CCR3 | P51677 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Difenoxin SCHEMBL11604884 | 1.00 | KCNA3 (0.76) | KCNA3OPRM1CCR1RAB9ANPSR1 | |
| Difenoxin SCHEMBL123801 | 0.99 | KCNA3 (0.78) | KCNA3OPRM1CCR1RAB9ANPSR1 | |
| SCHEMBL9106795 | 0.92 | CCR1 (0.70) | KCNA3OPRM1CCR1CCR3 | |
| Hydrochloric Acid SCHEMBL11604880 | 0.91 | KCNA3 (0.73) | KCNA3OPRM1CCR1RAB9ANPSR1 | |
| SCHEMBL11721054 | 0.90 | KCNA3 (0.66) | KCNA3OPRM1CCR1RAB9ANPSR1 | |
| SCHEMBL10064332 | 0.89 | KCNA3 (0.78) | KCNA3OPRM1CCR1RAB9ANPSR1 | |
| Diphenoxylate SCHEMBL8160138 | 0.89 | OPRM1 (0.94) | KCNA3OPRM1 | |
| SCHEMBL11604250 | 0.88 | KCNA3 (0.84) | KCNA3OPRM1CCR1RAB9ANPSR1 | |
| Hydrochloric Acid SCHEMBL11603407 | 0.88 | KCNA3 (0.70) | KCNA3OPRM1CCR1RAB9ANPSR1 | |
| SCHEMBL10065583 | 0.87 | KCNA3 (0.76) | KCNA3OPRM1CCR1RAB9ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 348 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150045764-A1 | SILK RESERVOIRS FOR DRUG DELIVERY | TRUSTEES OF TUFTS COLLEGE | 2015-02-12 | — | — | US | claimed |
| EP-2827884-A1 | SILK RESERVOIRS FOR DRUG DELIVERY | Trustees Of Tufts College (US) | 2015-01-28 | — | — | EP | claimed |
| WO-2013142611-A2 | SILK RESERVOIRS FOR DRUG DELIVERY | TRUSTEES OF TUFTS COLLEGE (US) | 2013-09-26 | — | — | WO | claimed |
| WO-2013142119-A1 | SILK RESERVOIRS FOR DRUG DELIVERY | TRUSTEES OF TUFTS COLLEGE (US) | 2013-09-26 | — | — | WO | claimed |
| EP-3129065-B1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | AKAMARA THERAPEUTICS INC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20260124324-A1 | PHOTOCLICK CHEMISTRY OF SILK FOR TEMPORARY UV TATTOOS | TUFTS COLLEGE (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4734896-A2 | BIOPOLYMER-BASED TYMPANOSTOMY TUBES WITH PROGRAMMABLE, TUNABLE, AND ON-DEMAND DEGRADATION | Trustees Of Tufts College (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735018-A2 | CENTRIFUGALLY-MOLDED ARTICLES AND METHODS | Trustees Of Tufts College (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12582612-B2 | Pharmaceutical composition of Siglec-binding agents | CYTODIGM, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12508305-B2 | Compositions and methods for treating and/or preventing glycogen storage disease type III | DUKE UNIVERSITY (US) | 2025-12-30 | — | — | US | disclosed |
| WO-2025227091-A1 | IMPROVED WHIPPED SILK CREAMS AND METHODS OF MAKING AND USING THE SAME | TRUSTEES OF TUFTS COLLEGE (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20250325495-A1 | SILK NANOPARTICLE SYNTHESIS: TUNING SIZE, DISPERSITY, AND SURFACE CHEMISTRY FOR DRUG DELIVERY | TUFTS COLLEGE (US) | 2025-10-23 | — | — | US | disclosed |
| WO-2001076631-A2 | METHODS FOR MANIPULATING UPPER GASTROINTESTINAL TRANSIT, BLOOD FLOW, AND SATIETY, AND FOR TREATING VISCERAL HYPERALGESIA | CEDARS-SINAI MEDICAL CENTER (US) | 2001-10-18 | — | — | WO | disclosed |
| US-6190692-B1 | Time-specific controlled release capsule formulations and method of preparing same | BUSETTI CESARE (IT) | 2001-02-20 | — | — | US | disclosed |
| EP-0954293-A1 | TIME-SPECIFIC CONTROLLED RELEASE DOSAGE FORMULATIONS AND METHOD OF PREPARING SAME | Polin Industria Chimica S.p.A. (IT) | 1999-11-10 | — | — | EP | disclosed |
| US-5977175-A | Methods and compositions for improving digestion and absorption in the small intestine | CEDARS-SINAI MEDICAL CENTER (US) | 1999-11-02 | — | — | US | disclosed |
| WO-1998032426-A1 | TIME-SPECIFIC CONTROLLED RELEASE DOSAGE FORMULATIONS AND METHOD OF PREPARING SAME | POLIN INDUSTRIA CHIMICA S.P.A. (IT) | 1998-07-30 | — | — | WO | disclosed |
| EP-0827402-A2 | COMPOSITIONS CONTAINING FATTY ACIDS FOR IMPROVING DIGESTION AND ABSORPTION IN THE SMALL INTESTINE | CEDARS-SINAI MEDICAL CENTER (US) | 1998-03-11 | — | — | EP | disclosed |
| WO-1996036330-A2 | COMPOSITIONS CONTAINING FATTY ACIDS FOR IMPROVING DIGESTION AND ABSORPTION IN THE SMALL INTESTINE | CEDARS-SINAI MEDICAL CENTER (US) | 1996-11-21 | — | — | WO | disclosed |
| WO-1992000082-A1 | ANTIDIARRHEAL COMPOSITIONS AND METHODS | THE PROCTER & GAMBLE COMPANY (US) | 1992-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124324-A1 | PHOTOCLICK CHEMISTRY OF SILK FOR TEMPORARY UV TATTOOS | PTMS, ITK, MATK | OPRM1 3032/4885KCNA3 3780/4885CCR1 3871/4885 |
| US-12508305-B2 | Compositions and methods for treating and/or preventing glycogen storage disease type III | GYS1, PYGM, RNGTT | OPRM1 4227/4885KCNA3 2818/4885CCR1 3293/4885 |
| US-12582612-B2 | Pharmaceutical composition of Siglec-binding agents | SIGLEC7, SIGLEC9, CD2 | OPRM1 271/4885KCNA3 1072/4885CCR1 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.